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INTRODUCTION
Hemophagocytic lymphohistiocytosis (HLH) is a 
life-threatening disorder characterized by excessive 
activation of the immune system causing tissue damage 
and organ dysfunction. Secondary HLH is more 
common in adults and is usually triggered by infection, 
malignancy, rheumatologic, and immunodeficiency 
syndromes. We present a case of HLH secondary to 
disseminated tuberculosis (TB). 
CASE PRESENTATION
A 72-year-old woman with past medical history of 
hypertension and type 2 diabetes presented to the 
emergency department for one day history of fevers, 
poor oral intake, and fatigue. She was febrile to 102.9 F 
and noted to have a toxic appearance, but there were no 
focal abnormalities found on exam. Initial blood work was 
notable for a mild direct hyperbilirubinemia of 2.5mg/dL, 
AST/ALT of 162/112 IU/L and elevated INR of 1.4. Abdominal 
ultrasound showed gallbladder wall thickening. Due to 
concerns for ascending cholangitis, ERCP was performed 
and revealed a normal biliary system. Day 2 of hospital-
ization revealed new pancytopenia - her white blood cell 
count was 2.7 B/L with 44% bands, hemoglobin was 10.8 
g/dL, and platelet count was 39 B/L. She also had rising 
hepatic function tests.  Her ferritin on day 3 was 
significantly elevated at 4149 IU/L, raising concerns for 
HLH.  On day 4, the patient became increasingly 
tachypneic and tachycardic with radiographic findings of 
pulmonary edema despite diuresis, as well as acute kidney 
injury with decreased urine output. She was intubated for 
increased work of breathing. Due to a high suspicion of 
HLH with the probability of HLH greater than 99% 
calculated by the HScore, methylprednisolone 120mg 
daily in split doses was initiated. Etoposide was not started 
due to her multiorgan dysfunction. On day 5, her liver and 
kidney failure worsened, and her ferritin and triglycerides 
continued to rise. She also developed hypofibrino-
genemia concerning for DIC. On day 6, methylpred-
nisolone was changed to dexamethasone 8mg Q6 and 
anakinra 100mg Q12 was added, but this was discontinued 
on day 7 when her liver biopsy showed many caseating 
and non-caseating granulomas with AFB stain positive for 
acid-fast bacilli. Sputum AFB stains were also obtained 
positive for acid fast bacilli. Sputum PCR showed 
Mycobacterium tuberculosis (TB) leading to the 
presumptive diagnosis of HLH secondary to disseminated 
TB.  Due to the patient’s acute liver failure, a modified 
regimen of TB treatment was initiated including rifampin, 
ethambutol, levofloxacin, and amikacin. Despite TB 
treatment, immunosuppression for HLH, and supportive 
measures, the patient continued to deteriorate and 
expired on day 10.  
DISCUSSION
Although HLH secondary to TB (TB-HLH) has previously 
been reported in the medical literature, it remains a rare 
entity.1 Most patients with TB-HLH had short symptom 
duration and rapid progression leading to multi-organ 
dysfunction and ultimately, death.
The first HLH treatment protocol was published in 1994 
(HLH-94) and has been widely used in clinical practice. 
HLH-94 includes an anti - inf lammatory agent , 
dexamethasone, and a pro-apoptotic agent, etoposide. 
This regimen has been shown to improve survival but was 
primarily based on data in the pediatric setting, many with 
primary HLH.2 Furthermore, etoposide was not determined 
to be a safe option due to her multi-organ dysfunction. 
Instead, anakinra, an IL-1 receptor antagonist was used in 
combination of dexamethasone. Anakinra as an immuno-
modulator has also been shown to be effective in the 
treatment of severe HLH in the critical care setting. 3-4  
Additionally, secondary HLH is often triggered by an acute 
infection or other condition (eg, rheumatologic condition) 
and treatment should be to address the underlying cause 
of immune activation. Although there is no consensus of 
standard treatment for TB-HLH, a systematic review of 
the international literature demonstrates that a delay or 
absence of antitubercular therapy (ATT) were associated 
with decreased survival.5  On the contrary, the combination 
of antitubercular therapy (ATT) with immunotherapy has 
been found to significantly reduce mortality.1 Our patient 
was initiated on a modified regimen of ATT as soon as the 
diagnosis of disseminated TB was made, but she still 
passed several days later. This case highlights the need for 
ongoing investigation for early detection and management 
of secondary HLH in the adult setting.
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